Open AccessEvaluation of a Nanoparticle-Based Busulfan Immunoassay for Rapid Analysis on Routine Clinical Analyzers
Author(s) -
Mary Rose Hilaire,
Regina V Gill,
Jodi B. Courtney,
Irina Baburina,
JoAnn Gardiner,
Michael C. Milone,
Leslie M. Shaw,
Qing H. Meng,
Salvatore J. Salamone
Publication year - 2021
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000883
Subject(s) - busulfan , chromatography , immunoassay , repeatability , chemistry , mass spectrometry , therapeutic drug monitoring , coefficient of variation , hematopoietic stem cell transplantation , transplantation , medicine , pharmacokinetics , pharmacology , surgery , immunology , antibody
Busulfan is an alkylating agent used in allogeneic hematopoietic stem cell transplantation for various malignant and nonmalignant disorders. Therapeutic drug monitoring of busulfan is common because busulfan exposure has been linked to veno-occlusive disease, disease relapse, and failed engraftment. The authors developed an automated immunoassay, along with stable calibrators and controls, and quantified busulfan in sodium heparin plasma.